Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia

키워드

참고문헌 (231)

1. Song JH, "Community-acquired pneumonia in the Asia-Pacific region", Semin Respir Crit Care Med, 37, pp.839~854 (2016)[DOI]
2. 윤형규, "Changes in the epidemiology and burden of community-acquired pneumonia in Korea", The Korean Journal of Internal Medicine, 29(6), pp.735~737 (2014), 대한내과학회[DOI]
3. 유광하, "Economic Burden and Epidemiology of Pneumonia in Korean Adults Aged over 50 Years", Journal of Korean Medical Science, 28(6), pp.888~895 (2013), 대한의학회
4. 성명길, "Healthcare-Associated Pneumonia among Hospitalized Patients: Is It Different from Community Acquired Pneumonia?", Tuberculosis and Respiratory Diseases, 76(2), pp.66~74 (2014), 대한결핵및호흡기학회
5. Kim JE, "Predictors of viral pneumonia in patients with community-acquired pneumonia", PLoS One, 9, pp.e114710~ (2014)[DOI]
6. 강윤성, "Antimicrobial Resistance and Clinical Outcomes in Nursing Home-Acquired Pneumonia, Compared to Community-Acquired Pneumonia", Yonsei Medical Journal, 58(1), pp.180~186 (2017), 연세대학교의과대학[DOI]
7. Jeong BH, "Performances of prognostic scoring systems in patients with healthcare-associated pneumonia", Clin Infect Dis, 56, pp.625~632 (2013)[DOI]
8. Eun Ju Jeon, "The Difference in Clinical Presentations between Healthcare-Associated and Community-Acquired Pneumonia in University-Affiliated Hospital in Korea", Yonsei Medical Journal, 52(2), pp.282~287 (2011), 연세대학교의과대학
9. Choi MJ, "Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes", J Infect Chemother, 21, pp.672~679 (2015)[DOI]
10. 정용필, "지역사회획득 폐렴의 원인 미생물에 대한 전향적 다기관 연구: 세균성 폐렴의 원인균 분석", Infection and Chemotherapy, 42(6), pp.397~403 (2010), 대한감염학회
11. Song JH, "Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens", Int J Antimicrob Agents, 31, pp.107~114 (2008)[DOI]
12. 손장욱, "Atypical Pathogens as Etiologic Agents in Hospitalized Patients with Community-Acquired Pneumonia in Korea: A Prospective Multi-Center Study", Journal of Korean Medical Science, 21(4), pp.602~607 (2006), 대한의학회
13. Lee SJ, "Atypical pathogens in adult patients admitted with community-acquired pneumonia in Korea", Jpn J Infect Dis, 55, pp.157~159 (2002)
14. Choi SH, "Viral infection in patients with severe pneumonia requiring intensive care unit admission", Am J Respir Crit Care Med, 186, pp.325~332 (2012)[DOI]
15. Mandell LA, "Infectious Diseases Society of America", American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults, 2007, pp.44(Suppl 2), S27~S72
16. Lim WS, "BTS guidelines for the management of community acquired pneumonia in adults: update 2009", Thorax, 64(Suppl 3), pp.iii1~iii55 (2009)
17. Song JH, "Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens", Clin Infect Dis, 38, pp.1570~1578 (2004)[DOI]
18. Kim SH, "Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study", Antimicrob Agents Chemother, 56, pp.1418~1426 (2012)[DOI]
19. 김시현, "부산 및 경남 4개 대학병원에서 분리된 폐렴알균의 분포 및 항균제 내성", Annals of Clinical Microbiology, 19(2), pp.48~53 (2016), 대한임상미생물학회
20. Kim T, "Fluoroquinolone resistance of Streptococcus pneumoniae isolates causing invasive disease: special focus on zabofloxacin", Diagn Microbiol Infect Dis, 86, pp.181~183 (2016)[DOI]
21. Lee S, "Changes in serotype prevalence and antimicrobial resistance among invasive Streptococcus pneumoniae isolates in Korea, 1996-2008", J Med Microbiol, 62, pp.1204~1210 (2013)[DOI]
22. Torumkuney D, "Results from the survey of antibiotic resistance (SOAR) 2012-14 in Thailand, India, South Korea and Singapore", J Antimicrob Chemother, 71(Suppl 1), pp.i3~i19 (2016)[DOI]
23. Bae S, "Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance", Antimicrob Agents Chemother, 54, pp.65~71 (2010)[DOI]
24. Kim IS, "Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea", Antimicrob Agents Chemother, 51, pp.453~460 (2007)[DOI]
25. Hong KB, "Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011", Emerg Infect Dis, 19, pp.1281~1284 (2013)[DOI]
26. 어영, "Macrolide Resistance of Mycoplasma pneumoniae and Its Detection Rate by Real-Time PCR in Primary and Tertiary Care Hospitals", Annals of Laboratory Medicine, 33(6), pp.410~414 (2013), 대한진단검사의학회
27. 손경목, "Post-influenza Pneumonia Caused by the USA300 Community- Associated Methicillin-Resistant Staphylococcus aureus in Korea", Journal of Korean Medical Science, 27(3), pp.313~316 (2012), 대한의학회
28. 임아영, "Comparison of Methicillin-Resistant Staphylococcus aureus Community-Acquired and Healthcare-Associated Pneumonia", Yonsei Medical Journal, 55(4), pp.967~974 (2014), 연세대학교의과대학[DOI]
29. 황지원, "Community-Acquired Necrotizing Pneumonia Caused by ST72-SCCmec Type IV-Methicillin-Resistant Staphylococcus aureus in Korea", Tuberculosis and Respiratory Diseases, 75(2), pp.75~78 (2013), 대한결핵및호흡기학회
30. Ruuskanen O, "Viral pneumonia", Lancet, 377, pp.1264~1275 (2011)[DOI]
31. Lieberman D, "Identification of respiratory viruses in adults: nasopharyngeal versus oropharyngeal sampling", J Clin Microbiol, 47, pp.3439~3443 (2009)[DOI]
32. Loens K, "Optimal sampling sites and methods for detection of pathogens possibly causing community-acquired lower respiratory tract infections", J Clin Microbiol, 47, pp.21~31 (2009)[DOI]
33. Prina E, "Community-acquired pneumonia", Lancet, 386, pp.1097~1108 (2015)[DOI]
34. Musher DM, "Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study", J Infect, 67, pp.11~18 (2013)[DOI]
35. Johansson N, "Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods", Clin Infect Dis, 50, pp.202~209 (2010)[DOI]
36. Johnstone J, "Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation", Chest, 134, pp.1141~1148 (2008)[DOI]
37. Falsey AR, "Bacterial complications of respiratory tract viral illness: a comprehensive evaluation", J Infect Dis, 208, pp.432~441 (2013)[DOI]
38. Jain S, "Community-acquired pneumonia requiring hospitalization among U.S. adults", N Engl J Med, 373, pp.415~427 (2015)[DOI]
39. Karhu J, "Lower respiratory tract virus findings in mechanically ventilated patients with severe community-acquired pneumonia", Clin Infect Dis, 59, pp.62~70 (2014)[DOI]
40. Musher DM, "Community-acquired pneumonia", N Engl J Med, 371, pp.1619~1628 (2014)[DOI]
41. Avni T, "Diagnostic accuracy of PCR alone and compared to urinary antigen testing for detection of Legionella spp.: a systematic review", Clin Microbiol, 54, pp.401~411 (2016)[DOI]
42. Maze MJ, "Enhanced detection of Legionnaires' disease by PCR testing of induced sputum and throat swabs", Eur Respir J, 43, pp.644~646 (2014)[DOI]
43. 조민철, "Comparison of Sputum and Nasopharyngeal Swab Specimens for Molecular Diagnosis of Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila", Annals of Laboratory Medicine, 32(2), pp.133~138 (2012), 대한진단검사의학회
44. Vikerfors T, "Detection of specific IgM antibodies for the diagnosis of Mycoplasma pneumoniae infections: a clinical evaluation", Scand J Infect Dis, 20, pp.601~610 (1988)[DOI]
45. Nilsson A, "Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection", BMC Microbiol, 8, pp.93~ (2008)[DOI]
46. Uldum SA, "Enzyme immunoassay for detection of immunoglobulin M (IgM) and IgG antibodies to Mycoplasma pneumoniae", J Clin Microbiol, 30, pp.1198~1204 (1992)
47. Parrott GL, "A compendium for Mycoplasma pneumoniae", Front Microbiol, 7, pp.513~ (2016)
48. Loens K, "Evaluation of different nucleic acid amplification techniques for the detection of M. pneumoniae, C. pneumoniae and Legionella spp. in respiratory specimens from patients with community-acquired pneumonia", J Microbiol Methods, 73, pp.257~262 (2008)[DOI]
49. Herrera M, "Comparison of serological methods with PCR-based methods for the diagnosis of community-acquired pneumonia caused by atypical bacteria", J Negat Results Biomed, 15, pp.3~ (2016)[DOI]
50. Villegas E, "Serological diagnosis of Chlamydia pneumoniae infection: limitations and perspectives", J Med Microbiol, 59, pp.1267~1274 (2010)[DOI]
51. Benitez AJ, "Comparison of real-time PCR and a microimmunofluorescence serological assay for detection of Chlamydophila pneumoniae infection in an outbreak investigation", J Clin Microbiol, 50, pp.151~153 (2012)[DOI]
52. Waterer GW, "Diagnosing viral and atypical pathogens in the setting of community-acquired pneumonia", Clin Chest Med, 38, pp.21~28 (2017)[DOI]
53. Syrjst H, "High-resolution computed tomography for the diagnosis of community-acquired pneumonia", Clin Infect Dis, 27, pp.358~363 (1998)[DOI]
54. Heffner JE, "Diagnostic utility and clinical application of imaging for pleural space infections", Chest, 137, pp.467~479 (2010)[DOI]
55. Arenas-Jimenez J, "Evaluation of CT findings for diagnosis of pleural effusions", Eur Radiol, 10, pp.681~690 (2000)[DOI]
56. Ketai L, "Imaging infection", Clin Chest Med, 36, pp.197~217 (2015)[DOI]
57. Raoof S, "Pictorial essay: multinodular disease: a high-resolution CT scan diagnostic algorithm", Chest, 129, pp.805~815 (2006)[DOI]
58. Revel MP, "Is it possible to recognize pulmonary infarction on multisection CT images?", Radiology, 244, pp.875~882 (2007)[DOI]
59. Shah RM, "CT angiogram sign: incidence and significance in lobar consolidations evaluated by contrast-enhanced CT", AJR Am J Roentgenol, 170, pp.719~721 (1998)[DOI]
60. Okada F, "Radiological findings in acute Haemophilus influenzae pulmonary infection", Br J Radiol, 85, pp.121~126 (2012)[DOI]
61. Miller WT Jr, "CT of viral lower respiratory tract infections in adults: comparison among viral organisms and between viral and bacterial infections", Am J Roentgenol, 197, pp.1088~1095 (2011)[DOI]
62. Nambu A, "Chlamydia pneumoniae: comparison with findings of Mycoplasma pneumoniae and Streptococcus pneumoniae at thin-section CT", Radiology, 238, pp.330~338 (2006)[DOI]
63. Ors F, "High-resolution CT findings in patients with pulmonary tuberculosis: correlation with the degree of smear positivity", J Thorac Imaging, 22, pp.154~159 (2007)[DOI]
64. Koh WJ, "Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection", Radiology, 235, pp.282~288 (2005)[DOI]
65. Brenner DJ, "Computed tomography--an increasing source of radiation exposure", N Engl J Med, 357, pp.2277~2284 (2007)[DOI]
66. Volpicelli G, "International evidence-based recommendations for point-of-care lung ultrasound", Intensive Care Med, 38, pp.577~591 (2012)[DOI]
67. Chavez MA, "Lung ultrasound for the diagnosis of pneumonia in adults: a systematic review and meta-analysis", Respir Res, 15, pp.50~ (2014)[DOI]
68. Reissig A, "Lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia: a prospective, multicenter, diagnostic accuracy study", Chest, 142, pp.965~972 (2012)[DOI]
69. Kearney SE, "Computed tomography and ultrasound in parapneumonic effusions and empyema", Clin Radiol, 55, pp.542~547 (2000)[DOI]
70. Ramirez P, "Should ultrasound be included in the initial assessment of respiratory patients?", Lancet Respir Med, 2, pp.599~600 (2014)[DOI]
71. Sanyal S, "Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia", Am J Respir Crit Care Med, 160, pp.346~348 (1999)[DOI]
72. Woodhead MA, "Prospective study of the aetiology and outcome of pneumonia in the community", Lancet, 1, pp.671~674 (1987)
73. Menendez R, "Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia", Am J Respir Crit Care Med, 159, pp.1868~1873 (1999)[DOI]
74. Waterer GW, "The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures", Respir Med, 95, pp.78~82 (2001)[DOI]
75. Campbell SG, "The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study", Chest, 123, pp.1142~1150 (2003)[DOI]
76. Jefferson H, "Transportation delay and the microbiological quality of clinical specimens", Am J Clin Pathol, 64, pp.689~693 (1975)[DOI]
77. 김솔잎, "국내 일개 3차 병원에서 양성 NOW™ Legionella 소변 항원 검사의 임상적 의의", Annals of Laboratory Medicine, 26(2), pp.93~97 (2006), 대한진단검사의학회
78. Roson B, "Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia", Clin Infect Dis, 38, pp.222~226 (2004)[DOI]
79. Yzerman EP, "Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands", J Clin Microbiol, 40, pp.3232~3236 (2002)[DOI]
80. Arancibia F, "Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications", Am J Respir Crit Care Med, 162, pp.154~160 (2000)[DOI]
81. van der Eerden MM, "Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia", Eur J Clin Microbiol Infect Dis, 24, pp.241~249 (2005)[DOI]
82. Dominguez J, "Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples", Chest, 119, pp.243~249 (2001)[DOI]
83. Gutierrez F, "Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain", Clin Infect Dis, 36, pp.286~292 (2003)[DOI]
84. Murdoch DR, "Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia", J Clin Microbiol, 39, pp.3495~3498 (2001)[DOI]
85. Murdoch DR, "The NOW S. pneumoniae urinary antigen test positivity rate 6 weeks after pneumonia onset and among patients with COPD", Clin Infect Dis, 37, pp.153~154 (2003)[DOI]
86. Navarro D, "Performance of the Binax NOW Streptococcus pneumoniae urinary antigen assay for diagnosis of pneumonia in children with underlying pulmonary diseases in the absence of acute pneumococcal infection", J Clin Microbiol, 42, pp.4853~4855 (2004)[DOI]
87. Ortega L, "Utility of a pneumonia severity index in the optimization of the diagnostic and therapeutic effort for community-acquired pneumonia", Scand J Infect Dis, 37, pp.657~663 (2005)[DOI]
88. Smith MD, "Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation", J Clin Microbiol, 41, pp.2810~2813 (2003)[DOI]
89. Porcel JM, "Contribution of a pleural antigen assay (Binax NOW) to the diagnosis of pneumococcal pneumonia", Chest, 131, pp.1442~1447 (2007)[DOI]
90. Oka H, "The efficacy of high-dose penicillin for community-acquired pneumonia diagnosed by pneumococcal urine antigen test", J Infect Chemother, 15, pp.108~112 (2009)[DOI]
91. Birtles RJ, "Evaluation of urinary antigen ELISA for diagnosing Legionella pneumophila serogroup 1 infection", J Clin Pathol, 43, pp.685~690 (1990)[DOI]
92. Helbig JH, "Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella urinary enzyme immunoassay (EIA) and Biotest Legionella urin antigen EIA", J Med Microbiol, 50, pp.509~516 (2001)[DOI]
93. Alvarez J, "Impact of the Legionella urinary antigen test on epidemiological trends in community outbreaks of legionellosis in Catalonia, Spain, 1990-2004", Int J Infect Dis, 13, pp.365~370 (2009)[DOI]
94. Lim WS, "Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines", Thorax, 56, pp.296~301 (2001)[DOI]
95. Lee JS, "Short-term weight changes in community-dwelling older adults: the health, aging, and body composition weight change substudy", Am J Clin Nutr, 82, pp.644~650 (2005)[DOI]
96. Afshar N, "Blood cultures for community-acquired pneumonia: are they worthy of two quality measures? A systematic review", J Hosp Med, 4, pp.112~123 (2009)[DOI]
97. Metersky ML, "Predicting bacteremia in patients with community-acquired pneumonia", Am J Respir Crit Care Med, 169, pp.342~347 (2004)[DOI]
98. Labarere J, "Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: a propensity-adjusted analysis", Chest, 131, pp.480~488 (2007)[DOI]
99. Alikhan R, "Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study", Arch Intern Med, 164, pp.963~968 (2004)[DOI]
100. Minogue MF, "Patients hospitalized after initial outpatient treatment for community-acquired pneumonia", Ann Emerg Med, 31, pp.376~380 (1998)[DOI]
101. Neill AM, "Community acquired pneumonia: aetiology and usefulness of severity criteria on admission", Thorax, 51, pp.1010~1016 (1996)[DOI]
102. McMahon LF Jr, "Variation in hospital admissions among small areas. A comparison of Maine and Michigan", Med Care, 27, pp.623~631 (1989)[DOI]
103. Labarere J, "Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial", J Gen Intern Med, 21, pp.745~752 (2006)[DOI]
104. 송재훈, "지역사회획득 폐렴의 치료지침 권고안", Tuberculosis and Respiratory Diseases, 67(4), pp.281~302 (2009), 대한결핵및호흡기학회
105. Fine MJ, "A prediction rule to identify low-risk patients with community-acquired pneumonia", N Engl J Med, 336, pp.243~250 (1997)[DOI]
106. Lim WS, "Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study", Thorax, 58, pp.377~382 (2003)[DOI]
107. Aujesky D, "Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia", Am J Med, 118, pp.384~392 (2005)[DOI]
108. Bauer TT, "CRB-65 predicts death from community-acquired pneumonia", J Intern Med, 260, pp.93~101 (2006)[DOI]
109. Capelastegui A, "Validation of a predictive rule for the management of community-acquired pneumonia", Eur Respir J, 27, pp.151~157 (2006)[DOI]
110. Espana PP, "Development and validation of a clinical prediction rule for severe community-acquired pneumonia", Am J Respir Crit Care Med, 174, pp.1249~1256 (2006)[DOI]
111. Barlow G, "The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia", Thorax, 62, pp.253~259 (2007)[DOI]
112. Bont JE, "A prediction rule for elderly primary-care patients with lower respiratory tract infections", Eur Respir J, 29, pp.969~975 (2007)[DOI]
113. Man SY, "Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong", Thorax, 62, pp.348~353 (2007)[DOI]
114. Yealy DM, "Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial", Ann Intern Med, 143, pp.881~894 (2005)[DOI]
115. Atlas SJ, "Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial", Arch Intern Med, 158, pp.1350~1356 (1998)[DOI]
116. Marrie TJ, "A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL study investigators. Community-acquired pneumonia intervention trial assessing levofloxacin", JAMA, 283, pp.749~755 (2000)[DOI]
117. Suchyta MR, "Effects of a practice guideline for community-acquired pneumonia in an outpatient setting", Am J Med, 110, pp.306~309 (2001)[DOI]
118. Espana PP, "A prediction rule to identify allocation of inpatient care in community-acquired pneumonia", Eur Respir J, 21, pp.695~701 (2003)[DOI]
119. Ananda-Rajah MR, "Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia", Scand J Infect Dis, 40, pp.293~300 (2008)[DOI]
120. Abisheganaden J, "Predicting mortality among older adults hospitalized for community-acquired pneumonia: an enhanced confusion, urea, respiratory rate and blood pressure score compared with pneumonia severity index", Respirology, 17, pp.969~975 (2012)[DOI]
121. 김혜인, "Mortality of Community-Acquired Pneumonia in Korea: Assessed with the Pneumonia Severity Index and the CURB-65 Score", Journal of Korean Medical Science, 28(9), pp.1276~1282 (2013), 대한의학회
122. Lee JC, "Comparison of severity predictive rules for hospitalised nursing home-acquired pneumonia in Korea: a retrospective observational study", Prim Care Respir J, 22, pp.149~154 (2013)[DOI]
123. Niederman MS, "Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention", Am J Respir Crit Care Med, 163, pp.1730~1754 (2001)[DOI]
124. Chalmers JD, "Validation of the Infectious Diseases Society of America", American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care, 2011, pp.53, 503~511
125. Marti C, "Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis", Crit Care, 16, pp.R141~ (2012)[DOI]
126. Salih W, "Simplification of the IDSA", ATS criteria for severe CAP using meta-analysis and observational data, 2014, pp.43, 842~851
127. Charles PG, "SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia", Clin Infect Dis, 47, pp.375~384 (2008)[DOI]
128. Yandiola PPE, "Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia", Chest, 135, pp.1572~1579 (2009)[DOI]
129. Arnold FW, "A worldwide perspective of atypical pathogens in community-acquired pneumonia", Am J Respir Crit Care Med, 175, pp.1086~1093 (2007)[DOI]
130. Mills GD, "Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis", BMJ, 330, pp.456~ (2005)[DOI]
131. Eliakim-Raz N, "Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults", Cochrane Database Syst Rev, (9) (2012)
132. Postma DF, "Antibiotic treatment strategies for community-acquired pneumonia in adults", N Engl J Med, 372, pp.1312~1323 (2015)[DOI]
133. Lee MY, "In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries", Int J Antimicrob Agents, 28, pp.14~18 (2006)
134. Yu VL, "An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome", Clin Infect Dis, 37, pp.230~237 (2003)[DOI]
135. Noreddin AM, "Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP)", Int J Antimicrob Agents, 24, pp.479~484 (2004)[DOI]
136. File TM Jr, "Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia", Curr Med Res Opin, 20, pp.1473~1481 (2004)[DOI]
137. File TM Jr, "Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study", J Antimicrob Chemother, 60, pp.112~120 (2007)[DOI]
138. Gleason PP, "Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia", Arch Intern Med, 159, pp.2562~2572 (1999)[DOI]
139. Houck PM, "Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997", Chest, 119, pp.1420~1426 (2001)[DOI]
140. Dudas V, "Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals", Ann Pharmacother, 34, pp.446~452 (2000)[DOI]
141. Brown RB, "Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database", Chest, 123, pp.1503~1511 (2003)[DOI]
142. Garin N, "<TEX>${\beta}$<", TEX>-lactam monotherapy vs <TEX>${\beta}$<, JAMA Intern Med, pp.2014, 174[DOI]
143. Woodhead M, "Guidelines for the management of adult lower respiratory tract infections--full version", Clin Microbiol Infect, 17(Suppl 6), pp.E1~E59 (2011)
144. Paul M, "The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis", Eur Respir J, 30, pp.525~531 (2007)[DOI]
145. Ray WA, "Azithromycin and the risk of cardiovascular death", N Engl J Med, 366, pp.1881~1890 (2012)[DOI]
146. Trac MH, "Macrolide antibiotics and the risk of ventricular arrhythmia in older adults", CMAJ, 188, pp.E120~E129 (2016)[DOI]
147. Chang KC, "Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis", Eur Respir J, 35, pp.606~613 (2010)[DOI]
148. Chen TC, "Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis", Int J Infect Dis, 15, pp.e211~e216 (2011)[DOI]
149. Wang JY, "Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas", Thorax, 61, pp.903~908 (2006)[DOI]
150. Torres A, "Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial", Clin Infect Dis, 46, pp.1499~1509 (2008)[DOI]
151. Bhavnani SM, "Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with", without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia, 2008, pp.60, 59~64
152. Woodhead M, "Guidelines for the management of adult lower respiratory tract infections", Eur respir J, 26, pp.1138~1180 (2005)[DOI]
153. Rizzato G, "Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia", Eur respir J, 8, pp.398~402 (1995)[DOI]
154. Dunbar LM, "High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm", Clin Infect Dis, 37, pp.752~760 (2003)[DOI]
155. Schonwald S, "Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia", Eur J Clin Microbiol Infect Dis, 10, pp.877~880 (1991)[DOI]
156. Ramirez JA, "Switch therapy in community-acquired pneumonia", Diagn Microbiol Infect Dis, 22, pp.219~223 (1995)[DOI]
157. Ramirez JA, "Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia", Arch Intern Med, 159, pp.2449~2454 (1999)[DOI]
158. Ramirez JA, "Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia", Arch Intern Med, 161, pp.848~850 (2001)[DOI]
159. Castro-Guardiola A, "Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial", Am J Med, 111, pp.367~374 (2001)[DOI]
160. Nathan RV, "In-hospital observation after antibiotic switch in pneumonia: a national evaluation", Am J Med, 119, pp.512.e1~512.e7 (2006)[DOI]
161. Rhew DC, "A prospective, multicenter study of a pneumonia practice guideline", Chest, 114, pp.115~119 (1998)[DOI]
162. Halm EA, "Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia", Arch Intern Medicine, 162, pp.1278~1284 (2002)[DOI]
163. Capelastegui A, "Pneumonia: criteria for patient instability on hospital discharge", Chest, 134, pp.595~600 (2008)[DOI]
164. Halm EA, "Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines", JAMA, 279, pp.1452~1457 (1998)[DOI]
165. O'Driscoll BR, "BTS guideline for emergency oxygen use in adult patients", Thorax, 63(Suppl 6), pp.vi1~vi68 (2008)
166. Siempos II, "Adjunctive therapies for community-acquired pneumonia: a systematic review", J Antimicrob Chemother, 62, pp.661~668 (2008)[DOI]
167. Mismetti P, "Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials", Thromb Haemost, 83, pp.14~19 (2000)[DOI]
168. Dean NC, "Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia", Am J Med, 110, pp.451~457 (2001)[DOI]
169. Mundy LM, "Early mobilization of patients hospitalized with community-acquired pneumonia", Chest, 124, pp.883~889 (2003)[DOI]
170. File TM, "Community-acquired pneumonia", Lancet, 362, pp.1991~2001 (2003)[DOI]
171. Torres A, "Severe community-acquired pneumonia. Epidemiology and prognostic factors", Am Rev Respir Dis, 144, pp.312~318 (1991)[DOI]
172. Briones ML, "Assessment of analysis of urinary pneumococcal antigen by immunochromatography for etiologic diagnosis of community-acquired pneumonia in adults", Clin Vaccine Immunol, 13, pp.1092~1097 (2006)[DOI]
173. Leroy O, "Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors", Chest, 128, pp.172~183 (2005)[DOI]
174. Raz-Pasteur A, "Fluoroquinolones or macrolides alone versus combined with beta-lactams for adults with community-acquired pneumonia: systematic review and meta-analysis", Int J Antimicrob Agents, 46, pp.242~248 (2015)[DOI]
175. Lodise TP, "Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia", Antimicrob Agents Chemother, 51, pp.3977~3982 (2007)[DOI]
176. Baddour LM, "Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia", Am J Respir Crit Care Med, 170, pp.440~444 (2004)[DOI]
177. Martinez JA, "Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia", Clin Infect Dis, 36, pp.389~395 (2003)[DOI]
178. Waterer GW, "Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia", Arch Intern Med, 161, pp.1837~1842 (2001)[DOI]
179. Weiss K, "Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults", Can Respir J, 11, pp.589~593 (2004)[DOI]
180. Arancibia F, "Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis", Arch Intern Med, 162, pp.1849~1858 (2002)[DOI]
181. Kang CI, "Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli", Eur J Clin Microbiol Infect Dis, 27, pp.657~661 (2008)[DOI]
182. Kollef MH, "Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients", Chest, 115, pp.462~474 (1999)[DOI]
183. Murray RJ, "Community-acquired pneumonia due to pandemic A(H1N1)2009 influenza virus and methicillin resistant Staphylococcus aureus co-infection", PLoS One, 5, pp.e8705~ (2010)[DOI]
184. Bernardo K, "Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression", Antimicrob Agents Chemother, 48, pp.546~555 (2004)[DOI]
185. Micek ST, "Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production", Chest, 128, pp.2732~2738 (2005)[DOI]
186. Carpenter CF, "Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens", Clin Infect Dis, 38, pp.994~1000 (2004)[DOI]
187. Falagas ME, "Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline", Curr Drug Metab, 10, pp.13~21 (2009)[DOI]
188. Ruiz M, "Severe community-acquired pneumonia. Risk factors and follow-up epidemiology", Am J Respir Crit Care Med, 160, pp.923~929 (1999)[DOI]
189. Snijders D, "Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial", Am J Respir Crit Care Med, 181, pp.975~982 (2010)[DOI]
190. Meijvis SC, "Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial", Lancet, 377, pp.2023~2030 (2011)[DOI]
191. Torres A, "Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial", JAMA, 313, pp.677~686 (2015)[DOI]
192. Blum CA, "Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial", Lancet, 385, pp.1511~1518 (2015)[DOI]
193. Confalonieri M, "Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study", Am J Respir Crit Care Med, 171, pp.242~248 (2005)[DOI]
194. Marik P, "Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study", Chest, 104, pp.389~392 (1993)[DOI]
195. Monton C, "Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study", Eur Respir J, 14, pp.218~220 (1999)[DOI]
196. Annane D, "Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock", JAMA, 288, pp.862~871 (2002)[DOI]
197. Annane D, "Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome", Crit Care Med, 34, pp.22~30 (2006)[DOI]
198. Bruns AH, "Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia", Clin Infec Dis, 45, pp.983~991 (2007)[DOI]
199. Mittl RL Jr, "Radiographic resolution of community-acquired pneumonia", Am J Respir Crit Care Med, 149, pp.630~635 (1994)[DOI]
200. El Solh AA, "Radiographic resolution of community-acquired bacterial pneumonia in the elderly", J Am Geriatr Soc, 52, pp.224~229 (2004)[DOI]
201. Tang KL, "Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia", Arch Intern Med, 171, pp.1193~1198 (2011)[DOI]
202. Holmberg H, "Association of pneumonia and lung cancer: the value of convalescent chest radiography and follow-up", Scand J Infect Dis, 25, pp.93~100 (1993)[DOI]
203. Menendez R, "Markers of treatment failure in hospitalised community acquired pneumonia", Thorax, 63, pp.447~452 (2008)[DOI]
204. Chalmers JD, "C-reactive protein is an independent predictor of severity in community-acquired pneumonia", Am J Med, 121, pp.219~225 (2008)[DOI]
205. Menendez R, "Stability in community-acquired pneumonia: one step forward with markers?", Thorax, 64, pp.987~992 (2009)[DOI]
206. Coelho LM, "Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study", Crit Care, 16, pp.R53~ (2012)[DOI]
207. Hohenthal U, "Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia", Clin Microbiol Infect, 15, pp.1026~1032 (2009)[DOI]
208. Boussekey N, "Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia", Intensive Care Med, 32, pp.469~472 (2006)[DOI]
209. Lacoma A, "Usefulness of consecutive biomarkers measurement in the management of community-acquired pneumonia", Eur J Clin Microbiol Infect Dis, 31, pp.825~833 (2012)[DOI]
210. Schuetz P, "Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections", Cochrane Database Syst Rev (2017)
211. Schuetz P, "Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections", JAMA, 309, pp.717~718 (2013)[DOI]
212. de Jong E, "Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial", Lancet Infect Dis, 16, pp.819~827 (2016)[DOI]
213. Butler JC, "Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations", JAMA, 270, pp.1826~1831 (1993)[DOI]
214. Shapiro ED, "The protective efficacy of polyvalent pneumococcal polysaccharide vaccine", N Engl J Med, 325, pp.1453~1460 (1991)[DOI]
215. Moberley S, "Vaccines for preventing pneumococcal infection in adults", Cochrane Database Syst Rev, (1) (2008)
216. Maruyama T, "Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial", BMJ, 340, pp.c1004~ (2010)[DOI]
217. Christenson B, "Additive preventive effect of influenza and pneumococcal vaccines in elderly persons", Eur Respir J, 23, pp.363~368 (2004)[DOI]
218. Vila-Corcoles A, "Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study", Clin Infect Dis, 43, pp.860~868 (2006)[DOI]
219. Christenson B, "Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity", Virol J, 5, pp.52~ (2008)[DOI]
220. Fisman DN, "Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia", Clin Infect Dis, 42, pp.1093~1101 (2006)[DOI]
221. Mykietiuk A, "Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia", Eur J Clin Microbiol Infect Dis, 25, pp.457~462 (2006)[DOI]
222. Jackson LA, "Effectiveness of pneumococcal polysaccharide vaccine in older adults", N Engl J Med, 348, pp.1747~1755 (2003)[DOI]
223. Skull SA, "Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated", Vaccine, 25, pp.4631~4640 (2007)[DOI]
224. Jackson LA, "Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine", Vaccine, 23, pp.3697~3703 (2005)[DOI]
225. Torling J, "Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia", Vaccine, 22, pp.96~103 (2003)[DOI]
226. Waites KB, "Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine", J Spinal Cord Med, 31, pp.53~59 (2008)[DOI]
227. Nuorti JP, "Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team", N Engl J Med, 342, pp.681~689 (2000)[DOI]
228. Almirall J, "New evidence of risk factors for community-acquired pneumonia: a population-based study", Eur Respira J, 31, pp.1274~1284 (2008)[DOI]
229. Baik I, "A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women", Arch Intern Med, 160, pp.3082~3088 (2000)[DOI]
230. Marston BJ, "Surveillance for Legionnaires' disease: risk factors for morbidity and mortality", Arch Intern Med, 154, pp.2417~2422 (1994)[DOI]
231. West R, "Smoking cessation guidelines for health professionals: an update", Thorax, 55, pp.987~999 (2000)[DOI]

관련 논문AI추천